Meth-Related Cardiomyopathy: Where the Biggest Clusters Are
(MedPage Today) -- The American West has seen the biggest surge of cardiomyopathy-associated hospital admissions among methamphetamine users, based on 13 years of the latest available hospital admission data. The National Inpatient Sample (NIS... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 15, 2024 Category: Psychiatry Source Type: news

CT-FFR shows how smoking affects heart volume-to-myocardial mass ratio
Both current and former smokers show lower coronary volume-to-myocardial mass ratio (V/M) on CT fractional flow reserve (CT-FFR), researchers have found. In a study published March 14 in Radiology: Cardiothoracic Imaging, a team led by Kenneth Holmes, MD, of St Paul's Hospital and University of British Columbia in Vancouver, Canada, reported that smoking was associated with lower coronary volume-to-myocardial mass ratio in individuals with coronary artery disease (CAD) -- results that further cement the link between smoking and heart disease. "[We found that] current and former smoking were independently associated with ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News CT Cardiovascular Radiology Source Type: news

Dead lifts and death: sudden death due to hypertrophic cardiomyopathy in a body builder - Gupta R, Dsouza HL, Rai S, Shetty P, Rastogi P, Pp JR.
BACKGROUND: It is a well established fact that cardiac health and exercise go hand in hand.However, rigorous exercising regimens without proper cardiovascular screening can lead to catastrophic death in unsuspecting and otherwise healthy individuals. Among... (Source: SafetyLit)
Source: SafetyLit - March 4, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Viewpoint Collaborates with TriviumVet for Special Educational Episode on Feline Hypertrophic Cardiomyopathy and Pet Wellbeing
The educational program highlights a specific condition in cats... MIAMI, Feb. 22, 2024 /PRNewswire-PRWeb/ -- Renowned actor and host, Dennis Quaid, hosts the program Viewpoint, who have joined forces with TriviumVet to present an enlightening and educational episode centered around... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 22, 2024 Category: Pharmaceuticals Tags: PET Source Type: news

Mayo Clinic Minute: Know the warning signs of hypertrophic cardiomyopathy
It's often silent but can be a deadly killer. Hypertrophic cardiomyopathy is a genetic condition that occurs in 1 in 500 people. Dr. Said Alsidawi, a Mayo Clinic cardiologist, says the problem is that many people don't even know they have it because they have no symptoms. And in 20% of cases, the first presentation is sudden cardiac death.  Watch: The Mayo Clinic Minute https://youtu.be/M6RrnuAc_1M Journalists: Broadcast-quality video (1:07) is in the downloads at the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 20, 2024 Category: Databases & Libraries Source Type: news

How This Top 2% Biotech Overcame Two Obstacles And Doubled In A Month
has shucked off two high-profile setbacks, leading CYTK stock to double over a month as it looks to take on Big Pharma behemoth Bristol Myers Squibb (BMY) in heart disease treatment. Bristol Myers and Squibb are working to treat obstructive hypertrophic cardiomyopathy, or HCM, a genetic mutation…#bristolmyerssquibb #bmy #bristolmyers #squibb #hcm #cytokinetics #ubs #ashwaniverma #nvs #robertblum (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2024 Category: Consumer Health News Source Type: news

Man, 57, who had a heart transplant as a teen breaks world record to become longest-surviving recipient
Bert Janssen, from the Netherlands, was diagnosed with cardiomyopathy aged just 17, which makes it difficult for the heart to pump blood around the body. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2024 Category: Consumer Health News Source Type: news

Bridgebio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application Marketing Authorization Application accepted by the European Medicines... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 5, 2024 Category: Drugs & Pharmacology Source Type: news

S2 Episode 2: Genetic Cardiomyopathy: Get to the Heart of Family Risk S2 Episode 2: Genetic Cardiomyopathy: Get to the Heart of Family Risk
Drs Michelle Kittleson and Evan Kransdorf talk about when to test, how genetic testing should be interpreted, and what to do with the results.Medscape (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 16, 2024 Category: Radiology Tags: Cardiology InDiscussion Source Type: news

Acoramidis Beneficial in Transthyretin Amyloid Cardiomyopathy
THURSDAY, Jan. 11, 2024 -- Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2024 Category: Pharmaceuticals Source Type: news

Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians
Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health benefits, including reduced blood pressure levels and a reduction in a marker associated with hypertrophic cardiomyopathy and heart failure. (Source: NIEHS News)
Source: NIEHS News - January 11, 2024 Category: Environmental Health Source Type: news

Positive Topline Results for SEQUOIA-HCM Trial in OHCM Positive Topline Results for SEQUOIA-HCM Trial in OHCM
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 28, 2023 Category: Cardiology Tags: Cardiology Source Type: news

Women with dilated cardiomyopathy are twice as likely as men to need hospitalisation or a transplant within two years of diagnosis, study finds
A study has found that women with dilated cardiomyopathy - which causes the chambers of the heart to stretch, hindering its pumping action - are twice as likely as men to be hospitalised. (Source: the Mail online | Health)
Source: the Mail online | Health - December 17, 2023 Category: Consumer Health News Source Type: news

Tafamidis May Help Protect Cardiac Function in ATTR-CM Tafamidis May Help Protect Cardiac Function in ATTR-CM
Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 14, 2023 Category: Cardiology Tags: Cardiology Source Type: news

Bridgebio Pharma Announces Submission of New Drug Application to the FDA for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary endpoint (a hierarchical analysis prioritizing in... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 5, 2023 Category: Drugs & Pharmacology Source Type: news